Farnesyltransferase

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

Retrieved on: 
Thursday, May 13, 2021

b'SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.

Key Points: 
  • b'SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.
  • The Company\xe2\x80\x99s pipeline consists of small molecule drug candidates that target cancer signaling pathways.
  • Kura is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations.
  • For additional information about Kura, please visit the Company\xe2\x80\x99s website at www.kuraoncology.com .\n'

Global FTase (Farnesyltransferase) Inhibitor Pipeline Insight Report 2021: A Heterodimeric Zinc Enzyme that Belongs to the Transferases Family - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 9, 2021

This "FTase (Farnesyltransferase) inhibitor - Pipeline Insight, 2021" report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in FTase inhibitor pipeline landscape.

Key Points: 
  • This "FTase (Farnesyltransferase) inhibitor - Pipeline Insight, 2021" report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in FTase inhibitor pipeline landscape.
  • Farnesyltransferase (FTase) is a heterodimeric zinc enzyme that belongs to the transferases family.
  • Protein farnesyltransferase (FTase) is a two-subunit enzyme that is comprised by a 48 kDa-subunit and a 46 kDa-subunit.
  • FTase inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Proceeds from Priority Review Voucher Sale Will Fund Search for Cure for the Rapid Aging Disease Progeria

Retrieved on: 
Monday, November 23, 2020

PEABODY,Mass., Nov. 23, 2020 /PRNewswire/ --The Progeria Research Foundation (PRF) today announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher (PRV).

Key Points: 
  • PEABODY,Mass., Nov. 23, 2020 /PRNewswire/ --The Progeria Research Foundation (PRF) today announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher (PRV).
  • Zokinvy is a farnesyltransferase inhibitor (FTI) that has shown survival benefit in children with Progeria.
  • The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns, a child with Progeria.
  • PRF is the only non-profit organization solely dedicated to finding treatments and the cure for Progeria and its aging-related conditions, including heart disease.

Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria

Retrieved on: 
Tuesday, April 24, 2018

Children with Progeria live an average 14 years, dying from heart disease typically associated with old age.

Key Points: 
  • Children with Progeria live an average 14 years, dying from heart disease typically associated with old age.
  • Authors from Boston Children's Hospital and Brown University tracked more than 250 children from six continents to demonstrate a link between lonafarnib treatment and extended survival.
  • Lonafarnib, originally developed by Merck as a potential cancer therapeutic, inhibits farnesyltransferase, an enzyme that facilitates progerin production.
  • In the clinical trial, 27 children with Progeria received oral lonafarnib (150 mg/m2) twice daily as a monotherapy.